Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.60 |
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 5/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664740 | 0.83 | MAPT (0.64) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL6951600 | 0.80 | MAPT (0.60) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL4661622 | 0.80 | MAPT (0.60) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL3407787 | 0.80 | MAPT (0.60) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL29851934 | 0.80 | MAPT (0.60) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL10597685 | 0.80 | MAPT (0.60) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL14759038 | 0.80 | MAPT (0.60) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL1133533 | 0.80 | MAPT (0.55) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL30590658 | 0.78 | MAPT (0.57) | KMT2AMAPTMEN1ALDH1A1GAA | |
| SCHEMBL4661873 | 0.78 | MAPT (0.57) | KMT2AMAPTMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507494-B2 | Heterocyclic quinolizine derived M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130040959-A1 | Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2013-02-14 | — | — | US | disclosed |
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | KMT2A 4086/4885MAPT 3706/4885MEN1 1683/4885 |
| US-20130040959-A1 | Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, CHRNA5 | KMT2A 1205/4885MAPT 494/4885MEN1 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.